Literature DB >> 32536469

First Trial of CRISPR-Edited T cells in Lung Cancer.

Simon F Lacey1, Joseph A Fraietta2.   

Abstract

The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2020        PMID： 32536469     DOI： 10.1016/j.molmed.2020.06.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  8 in total

1.  CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa.

Authors:  Wen-Hsuan Wu; Yi-Ting Tsai; I-Wen Huang; Chia-Hua Cheng; Chun-Wei Hsu; Xuan Cui; Joseph Ryu; Peter M J Quinn; Salvatore Marco Caruso; Chyuang-Sheng Lin; Stephen H Tsang
Journal:  Mol Ther       Date:  2022-02-10       Impact factor: 12.910

Review 2.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

Review 3.  Targeting Cancer with CRISPR/Cas9-Based Therapy.

Authors:  Katarzyna Balon; Adam Sheriff; Joanna Jacków; Łukasz Łaczmański
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

Review 4.  The Potential of CRISPR-Guided Therapies in the Dermatology Clinic.

Authors:  Prashant Bhat; Lilit Garibyan
Journal:  JID Innov       Date:  2022-01-25

Review 5.  Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.

Authors:  Yanxin Xu; Chen Chen; Yaxin Guo; Shengyun Hu; Zhenqiang Sun
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

Review 6.  Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer.

Authors:  Shuo Yang; Yang Huang; Qi Zhao
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

7.  Computational normal mode analysis accurately replicates the activity and specificity profiles of CRISPR-Cas9 and high-fidelity variants.

Authors:  Oded Shor; Roy Rabinowitz; Daniel Offen; Felix Benninger
Journal:  Comput Struct Biotechnol J       Date:  2022-04-20       Impact factor: 6.155

Review 8.  A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing.

Authors:  Xin-Zhu Chen; Rong Guo; Cong Zhao; Jing Xu; Hang Song; Hua Yu; Christian Pilarsky; Firzan Nainu; Jing-Quan Li; Xin-Ke Zhou; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.